7 completed. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 3 | Completed 3 |
Follow Ataxia: new trials by email Literature Review of Ataxia trials Research Report on Ataxia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Elimusertib (BAY1895344), Pembrolizumab (Keytruda®) - Advanced Solid Tumors | Phase 1 | Completed | Bayer | 56 | 2019-09-30 | 2024-04-02 |
| A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome dantrolene sodium - Wolfram Syndrome, Diabetes Mellitus | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 21 | 2017-01-01 | 2024-03-13 |
| A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors thioureidobutyronitrile - Solid Tumors | Phase 1 | Completed | Cellceutix Corporation | 48 | 2012-10-01 | 2016-02-24 |
| Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells Allogeneic adult adipose-derived mesenchymal stem cells - Cerebellar Ataxia | Phase 1 / Phase 2 | Completed | National Yang Ming Chiao Tung University | 7 | 2012-05-01 | 2014-09-12 |
| Lithium Treatment for Patients With Spinocerebellar Ataxia Type I Lithium Carbonate - Spinocerebellar Ataxia Type I | Phase 1 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 13 | 2008-05-18 | 2019-12-17 |
| Effectiveness of Rituximab in Pediatric OMS Patients. rituximab - Opsoclonus-myoclonus Syndrome, Opsoclonus | Phase 1 / Phase 2 | Completed | National Pediatric Neuroinflammation Organization, Inc. | 25 | 2005-06-01 | 2011-05-10 |
| Safety of RG2077 in Patients With Multiple Sclerosis RG2077 (CTLA4-IgG4m) - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2003-01-01 | 2017-03-27 |
Spinocerebellar Ataxias (2) · Ataxia Telangiectasia (1) · Autoimmune Diseases (1) · Carcinoma (1) · Cerebellar Ataxia (1) · Diabetes Mellitus (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Myoclonus (1) · Neoplasms (1) · Ocular Motility Disorders (1) · Opsoclonus-Myoclonus Syndrome (1) · Optic Atrophy (1)
Dyskinesias (7) · Nervous System Diseases (7) · Neurologic Manifestations (7) · Central Nervous System Diseases (5) · Neurodegenerative Diseases (5) · Brain Diseases (4) · Cerebellar Diseases (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Heredodegenerative Disorders, Nervous System (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Cerebellar Ataxia (3) · Congenital Abnormalities (2)
BAY 1895344 (1) · Dantrolene (1) · Lithium Carbonate (1) · Rituximab (1) · pembrolizumab (1)
Bayer (1) · Cellceutix Corporation (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · National Pediatric Neuroinflammation Organization, Inc. (1) · National Yang Ming Chiao Tung University (1) · Washington University School of Medicine (1)
United States (6) · Germany (1) · Spain (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Fumihiko Urano, MD (1) · Geoffrey Shapiro, MD PhD (1) · Grisel J Lopez, M.D. (1) · Michael R Pranzatelli, M.D. (1) · Samia J. Khoury, MD (1)
PMID 18794494, PMID 19838774, PMID 20606544, PMID 21211990, PMID 34185708
2018 (1), R21DK113487 (1)